Gsk-3α and Gsk-3β, are constitutively active, largely inhibitory kinases involved in signal transduction. Underscoring their biological significance, altered Gsk-3 activity has been implicated in diabetes, Alzheimer's disease, schizophrenia, and bipolar disorder. Here, we demonstrate that deletion of both Gsk-3α and Gsk-3β in mouse embryonic stem cells (ESCs) results in reduced expression of the de novo DNA methyltransferase Dnmt3a2, causing misregulated expression of the imprinted genes Igf2, H19, and Igf2r and hypomethylation of their corresponding imprinted control regions (ICR). Treatment of wild-type ESCs and neural stem cells with the Gsk-3 inhibitor, lithium, phenocopies the DNA hypomethylation at these imprinted loci. We show that inhibition of Gsk-3 by phosphatidylinositol 3-kinase (PI3K) mediated activation of AKT kinase also results in reduced DNA methylation at these imprinted loci. Finally, we find N-myc is a potent Gsk-3-dependent regulator of Dnmt3a2 expression. In summary, we have identified a signal transduction pathway that is capable of altering the DNA methylation of imprinted loci.
Glycogen synthase kinase-3 (Gsk-3) isoforms,
Gsk-3α and Gsk-3β, are constitutively active, largely inhibitory kinases involved in signal transduction. Underscoring their biological significance, altered Gsk-3 activity has been implicated in diabetes, Alzheimer's disease, schizophrenia, and bipolar disorder. Here, we demonstrate that deletion of both Gsk-3α and Gsk-3β in mouse embryonic stem cells (ESCs) results in reduced expression of the de novo DNA methyltransferase Dnmt3a2, causing misregulated expression of the imprinted genes Igf2, H19, and Igf2r and hypomethylation of their corresponding imprinted control regions (ICR). Treatment of wild-type ESCs and neural stem cells with the Gsk-3 inhibitor, lithium, phenocopies the DNA hypomethylation at these imprinted loci. We show that inhibition of Gsk-3 by phosphatidylinositol 3-kinase (PI3K) mediated activation of AKT kinase also results in reduced DNA methylation at these imprinted loci. Finally, we find N-myc is a potent Gsk-3-dependent regulator of Dnmt3a2 expression. In summary, we have identified a signal transduction pathway that is capable of altering the DNA methylation of imprinted loci.
Gsk-3 is functionally defined as the aggregate activity of both Gsk-3α and Gsk-3β isoforms which are encoded at distinct genetic loci. These highly redundant kinases are constitutively active, and generally play an inhibitory role in the signal transduction pathways which they regulate (1), such as insulin signaling and canonical Wnt signaling (2) . In addition, Gsk-3 has a major role in regulating differentiation of embryonic stem cells (3) and neural progenitors (4) . Both insulin and Wnt signaling have been implicated in the regulation of stem cell pluripotency (5) (6) (7) (8) (9) (10) (11) (12) (13) . Insulin signaling modulates Gsk-3 activity via the activity of upstream effectors: insulin or insulinlike growth factor binds to the insulin receptor, resulting in the activation of PI3K, which in turn phosphorylates and activates Akt (also called protein kinase B; PKB) (14). Akt subsequently phosphorylates several substrates, including Gsk-3 isoforms, on N-terminal serine residues (Gsk-3α S21/Gsk-3β S9), resulting in the inhibition of Gsk-3 activity (15) .
Gsk-3 activity also represents a key regulatory step in the canonical Wnt signaling pathway. In the absence of ligand, a subset of cytoplasmic Gsk-3 is found in a protein complex which facilitates Gsk-3-mediated phosphorylation of β-catenin, targeting the protein for ubiquitination and degradation via the 26S proteasome, and keeping the Wnt pathway repressed (16) . Upon ligand binding to the Wnt co-receptors, Gsk-3 redistributes to the cell surface (17) , rendering the β-catenin destruction complex non-functional, causing the accumulation and subsequent nuclear translocation of β-catenin protein, which leads to the transcription of Wnt target genes. While activated insulin and Wnt signaling both inhibit Gsk-3 activity, the mechanism of inhibition is distinct for each pathway; Wnt signaling does not affect insulin signaling, and insulin signaling does not activate Wnt target genes (18, 19) .
Gsk-3 function in the insulin and Wnt signaling pathways has been thoroughly investigated, and numerous substrates of Gsk-3 have been described (2) , yet the downstream effects of such a widelyinfluential enzyme likely extend beyond our current knowledge. Here, we present evidence of a novel role for Gsk-3 isoforms in the regulation of DNA methylation at imprinted loci in mouse ESCs. The de novo DNA methyltransferase, Dnmt3a2, is downregulated in Gsk-3 DKO ESCs, resulting in reduced DNA methylation and altered expression of imprinted genes. Inhibition of Gsk-3 activity with lithium mimics the effects on reducing DNA methylation in both wild-type ESCs and wild-type neural stem cells. Furthermore, inactivation of Gsk-3 via components of the insulin signaling pathway results in reduced DNA methylation at imprinted loci. Finally, microarray data reveals that N-myc mRNA is down-regulated in Gsk-3 DKO ESCs.
We provide data which demonstrate that a highly conserved N-myc binding site in the Dnmt3a2 promoter is required for normal expression, and we demonstrate that siRNA knockdown of N-myc results in a decrease in Dnmt3a2 expression. Therefore, we have identified a novel function for Gsk-3 isoforms as key regulators of the epigenome, and our results add a new perspective on the consequences of altering Gsk-3 activity.
Experimental Procedures
Cell Culture -Feeder-free wild-type, Gsk-3α -/-, Gsk-3β -/-, Gsk-3 DKO ESCs (3) were grown on gelatin-coated plates in high glucose DMEM (GIBCO) supplemented with 15% fetal bovine serum (Hyclone), 1X non-essential amino acids, 1X sodium pyruvate, 2mM L-glutamine, 1X penicillin/streptomycin (GIBCO), 55µM 2-mercaptoethanol, and 1000 units/ml ESGRO (Millipore). Media was replenished every other day. Neural stem cells were isolated from 12.5 dpc embryos using NeuroCult NSC Proliferation Media (StemCell Technologies) following the manufacturer's protocol.
Microarray analysis -Integrity of total RNA was evaluated using capillary electrophoresis (Bioanalyzer 2100, Agilent) and quantified using a Nanodrop 1000 (Nanodrop, Wilmington, DE). Following confirmation of RNA quality, Ovation™ Biotin RNA Amplification and Labeling System (NuGen Technologies, Inc., San Carlos, CA) was used to prepare amplified, biotinlabeled cDNA from total RNA for following manufacturer's instructions. Briefly, first strand cDNA was synthesized from 25 ng of total RNA using a unique first strand DNA/RNA chimeric primer and reverse transcriptase. Following double strand cDNA generation, amplification of cDNA was achieved by utilizing an isothermal DNA amplification process that involves repeated SPIA™ DNA/RNA primer binding, DNA duplication, strand displacement and RNA cleavage. The amplified SPIA™ cDNA was purified and subjected to a two-step fragmentation and labeling process. The fragmented/biotinylated cDNA content was measured in a ND-1000 spectrophotometer and the quality was analyzed on an RNA 6000 Nano LabChip (Agilent) using AgilentBioanalyzer2100.
For each array, 2.2 µg of cDNA was hybridized onto Mouse Genome 430 2.0 GeneChips® (Affymetrix Inc., USA), that contain approximately 39,000 transcripts. The sequences from which these probe sets were derived were selected from GenBank®, dbEST, and RefSeq. The sequence clusters were created from the UniGene database (Build 107, June 2002) and then refined by analysis and comparison with the publicly available draft assembly of the mouse genome from the Whitehead Institute for Genome Research (MGSC, April 2002). Hybridization was allowed to continue for 16 hours at 45ºC followed by washing and staining of microarrays in a Fluidics Station 450 (Affymetrix Inc., USA). GeneChips were scanned in a GeneChip Scanner 3000 (Affymetrix Inc., USA) and CEL files were generated from DAT files using GeneChip® Operating Software (GCOS) software (Affymetrix Inc., USA). The probe set signals were generated using the RMA algorithm in ArrayAssist 3.4 (Stratagene) and were used to determine differential gene expression by pair-wise comparisons. The genes that were altered by twofold either way and had a false discovery rate (FDR) of <10% were sorted and used for further (5); from Shinya Yamanaka, Addgene plasmid 15689) expressed a hygromycin-resistance cassette. ES cells were transfected with either the Dnmt3a2 or p110* expression constructs with Lipofectamine 2000 (Invitrogen) in serum free OPTI-MEM (GIBCO). Cells were allowed to recover in nonselective ES cell media for 24 hours, after which puromycin-resistant (Dnmt3a2) or hygromycinresistant (p110*) cells were grown in ES cell media containing 1 µg/ml puromycin or 200 µg/ml hygromycin, respectively. Puromycin/ hygromycin-resistant colonies were isolated after 14 days of selection and expanded in selective media. Dnmt3a2 Reporter Assays -The Dnmt3a2 promoter was cloned by PCR amplification from BAC clone 330c18 RPCI-24 BAC library using primers described in Table S1 . Amplification products were TOPO TA cloned into pCR8GW (Invitrogen), and then transferred by LR reaction to Gateway-modified pGL3-Basic, pGLF (from Glenn Maston, University of Massachusetts). Mutagenesis of the N-myc binding site was accomplished by using the Quick Change II sitedirected mutagenesis kit (Stratagene) ( Table S1 ). Plasmids containing the Dnmt3a2 promoter constructs driving firefly luciferase, were cotransfected into ESCs with pRL SV40 with Lipofectamine 2000 (Invitrogen) in serum free OPTI-MEM (GIBCO). Cells were replated in a 24-well plate 24 hours post transfection, then lysed 48 hours post transfection, at which time Firefly and Renilla Luciferase assays were performed according to the manufacturer's protocol (Biotium) in a Veritas microplate luminometer (Turner Biosystems). Three replicates were performed for each transfection. Antibodies and Protein Expression AnalysisProtein expression was assayed by western blotting. Cells were resupended in lysis buffer (137 mM NaCl, 10 mM Tris pH 7.4, 1% NP-40) containing protease inhibitor cocktail (1:100 Sigma), sonicated for 10 30-second pulses at 4°C in a Bioruptor (Diagenode) on the highest setting. Lysates were electrophoresed (8-20 mg/lane) through 7.5% tris/tricine gels and transferred onto nitrocellulose membrane (Whatman BA85) at 100V for 1 hour. Blots were blocked for 1 hour with 5% milk/TBST (150 mM NaCl, 50 mM Tris pH 7.4, 0.1% Tween) and incubated in primary antibody diluted in 5% milk or 5% BSA (N-myc and c-myc antibodies) TBST 16-18 hours at 4°C. Antibodies were used under the following conditions: Anti-tubulin mouse mAb clone B-5-1-2 (Sigma) was diluted 1:10,000; Anti-Dnmt3a mouse mAb clone 64B1446 (IMGENEX) was diluted 1:250; anti-GSK-3α/β mouse mAb clone 1H8 (Calbiochem), anti-phospho-GSK-3α/β (Cell Signaling #9331), anti-N-myc (Cell Signaling #9405), anti-c-myc D84C12 XP (Cell Signaling #5605), anti-PI3kinase p110α subunit C73F8 (Cell Signaling #4249), anti-Akt1 2H10 (Cell Signaling #2967), anti-phospho-Akt Ser 473 193H12 (Cell Signaling #4058) were all used at a 1:1000 dilution. Blots were incubated in anti-mouse or anti-rabbit IgG HRP secondary antibody (GE Healthcare) diluted 1:5000 in 5% milk in TBST for 45 minutes. Proteins were visualized using ECL detection reagent (GE Healthcare). Blots were stripped in a buffer consisting of 2% SDS, 62.5 mM Tris HCl pH 6.7, and 100 mM β-mercaptoethanol at 50°C for 30 minutes followed by repeated rinsing with TBST prior to reprobing with antibody. DNA Isolation -High molecular weight genomic DNA was isolated after ESCs were washed in PBS, and resupended in lysis buffer (100 mM NaCl, 10 mM Tris pH 8.0, 25 mM EDTA pH 8.0, 0.5% SDS) and lysed 16-18 hours at 55°C. An equal volume of phenol:chloroform:isoamyl alcohol was added and gently rotated at ambient temperature for 2-3 hours. DNA was precipitated with twice volume of ethanol and 0.1 volume sodium acetate, washed in 70% ethanol, and resuspended in sterile water. Southern Blot -High molecular weight genomic DNA was digested with methylation sensitive HpaII or methylation insensitive MspI isoschizomers (New England Biolabs). Digested DNA was separated on 0.6% agarose in 0.5X by guest on August 17, 2017 http://www.jbc.org/ Downloaded from TAE, and transferred to charged nylon membrane (Osmonics Inc.). The blot was hybridized with a 32 P-α -dCTP random primed labeled (Prime-It II, Stratagene) IAP probe (20) 
Three biological replicates and three technical replicates were used for each target analyzed. All threshold cycle (Ct) values were normalized to a mouse GAPDH endogenous control (Applied Biosystems), and relative quantitation was calculated from the median Ct value. Bisulfite Sequencing -High molecular weight genomic DNA was fragmented by rapid freezing on dry ice and thawing at 42°C for 5 repetitions. 500 ng of fragmented DNA was bisulfite converted with the Methyl Code Bisulfite Conversion Kit (Invitrogen) per manufacturer's instructions. Igf2/H19 DMD and Igf2r DMR2 were amplified from bisulfite converted DNA with Platinum Taq (Invitrogen) using primers shown in Table S1 (22) and the following conditions: 94°C 10', 35 cycles of (94°C 45", 54°C 45", 72°C 60") followed by 72°C 7'. PCR products were then TOPO TA cloned into pCR8GW (Invitrogen). Plasmid clones were sequenced with M13 Reverse primer (Table S1 ) using Big Dye version 3.1 chemistry with the following conditions: 96°C 10", then 25 cycles of (96°C 10", 50°C 5", 60°C 4'), and reaction products were resolved on an Applied Biosystems 3130XL Genetic Analyzer. -/-ESCs (increased 1.1 fold in each). In addition to full-length Dnmt3a, there is a distinct smaller isoform, Dnmt3a2, which is transcribed from an alternative promoter within the Dnmt3a locus. Dnmt3a2 lacks the amino-terminal 219 amino acids found in Dnmt3a, but the remainder of the protein, including the domain containing methyltransferase activity, is identical between the isoforms (23) .
RESULTS

Expression of the de novo DNA Methyltransferase Dnmt3a2 is Reduced in Gsk-3 DKO ESCs -
Importantly for this study, Dnmt3a2 is the isoform that is predominantly expressed in ESCs (24) . The microarray probes are unable to differentiate between Dnmt3a isoforms, and the microarray expression data represents a composite of the expression of both Dnmt3a and Dnmt3a2. Therefore, we evaluated the protein expression of each individual isoform, as the individual isoforms can be resolved by immunoblotting. We found that Dnmt3a2 protein expression is substantially reduced in Gsk-3 DKO cells, while Dnmt3a protein levels were essentially unchanged ( Figure 1A) . Real-time quantitative PCR (qPCR) revealed mRNA expression of Dnmt3a2 is reduced 2.7 fold in Gsk-3 DKO ESCs when compared to WT ESCs ( Figure 1B) . Imprinted Loci Display Altered Gene Expression and DNA Methylation in Gsk-3 DKO ESCsDnmt3a/Dnmt3a2 activity is required for the establishment of DNA methylation at imprinted loci in germ cells (25) . Mouse ESCs null for both Dnmt3a and Dnmt3b lose DNA methylation at imprinted loci after extended passaging, demonstrating a role for the de novo methyltransferases in the maintenance of DNA methylation at imprinted loci. Notably, reexpression of Dnmt3a2 alone in Dnmt3a -/-; Dnmt3b -/-ESCs is sufficient to fully restore DNA methylation at paternally imprinted loci, whereas re-expression of Dnmt3a or Dnmt3b1 is only able to minimally rescue DNA methylation at these loci (26) . Based on these published observations, we hypothesized that reduction of Dnmt3a2 expression in ESCs would result in loss of DNA methylation and disruption of gene expression at imprinted loci. The imprinted locus containing the genes insulin-like growth factor II (Igf2) and H19 has been well characterized. The reciprocal expression of Igf2 and H19 is regulated by a shared imprinting control region (ICR) designated the differentially methylated domain (DMD) (27) (28) (29) . In this ICR, the paternal allele is methylated, resulting in expression of Igf2 and silencing of H19, while conversely, the maternal allele is unmethylated, promoting H19 expression while silencing Igf2 (30) . Indeed, the imprinted genes H19 and Igf2 display altered expression in Gsk-3 DKO ESCs when compared to WT ESCs. Igf2 and H19 expression in Gsk-3 DKO cells was assayed by qPCR, and H19 expression is increased 1.4 fold, while Igf2 expression is decreased 100 fold ( Figure 1C ). This pattern of gene expression is consistent with a scenario for loss of DNA methylation at the Igf2/H19 DMD (29, 31, 32) . We directly measured DNA methylation of the Igf2/H19 DMD by bisulfite sequencing, and find a 47% reduction of DNA methylation in Gsk-3 DKO ESCs compared to WT ESCs ( Figure 1D ). These results strongly support the hypothesis that the alterations in Igf2 and H19 expression are due to a loss of DNA methylation at the Igf2/H19 DMD.
Expression of Air, another imprinted gene which encodes for a long non-coding RNA (34) , is increased in Gsk-3 DKO ESCs. Air mRNA expression in Gsk-3 DKO ESCs was assayed by qPCR, and is increased by 3.8 fold (Figure 2A) . We then determined if the change in expression of Air is due to a loss of DNA methylation. We performed bisulfite sequencing on differentially methylated region 2 (DMR2) of Igf2r, from which Air is transcribed and known to be methylated on the maternal allele (22, 35) . DNA methylation at DMR2 is reduced by 67% in Gsk-3 DKO ESCs ( Figure 2B ). These data suggest that the increase in Air expression is likely due to DNA hypomethylation within the Igf2r DMR2, and demonstrates that the loss of Gsk-3 activity on DNA methylation extends beyond the Igf2/H19 DMD, supporting a possible broader role for Gsk-3 in the regulation of imprinted genes in the mouse.
Global DNA Methylation is Unchanged in Gsk-
Repetitive DNA sequences, such as Intracisternal A particle (IAP) repeats, are highly methylated in WT mouse ESCs (37) , and largely unmethylated in Dnmt1 -/-and Dnmt1 hypomorph ESCs (38) .
IAP repeat methylation, although reduced, is largely retained in ESCs deficient in de novo DNA methyltransferase activity (Dnmt3a -/-; Dnmt3b -/-) (38, 39) . Therefore, analyzing DNA methylation of IAP repeats provides an assay for Dnmt1 activity. Southern blotting using methylationsensitive restriction enzymes revealed that Gsk-3 DKO ESCs do not exhibit a significant difference in DNA methylation of IAP repeats compared to wild-type ESCs ( Figure 2C ), suggesting there is not a general defect in DNA maintenance methylation in Gsk-3 DKO cells. This data strengthens our hypothesis that the loss of DNA methylation observed at imprinted loci in Gsk-3 DKO ESCs is likely the result of specific downregulation of Dnmt3a2 expression.
Ectopic Expression of Dnmt3a2 in Gsk-3 DKO ESCs Rescues the Deficits in DNA Methylation -
To evaluated whether exogenous expression of Dnmt3a2 could rescue the loss of DNA methylation at imprinted loci in Gsk-3 DKO ESCs, we isolated puromycin-resistant Gsk-3 DKO ESCs stably expressing Dnmt3a2 under the control of the chicken β-actin (CAG) promoter, and evaluated DNA methylation at the Igf2/H19 DMD by bisulfite sequencing. A puromycin resistant clone in which Dnmt3a2 is stably overexpressed in DKO ESCs (Dnmt3a2) was selected for bisulfite sequencing analysis, and a puromycin-resistant clone that does not overexpress Dnmt3a2 (vector) served as a negative control ( Figure 3A) . Bisulfite sequencing of the Igf2/H19 DMD revealed that DNA methylation is restored to levels previously observed in WT ESCs in the overexpressing clone (92.7%; Figure 3B) Figure 4A ). Next we examined the effect of Gsk-3 inhibitors on DNA methylation in a cell type other than ESCs. Because the Gsk-3 inhibitor lithium is used clinically to treat bipolar disorder, we chose to use cells from the neuronal lineage, specifically mouse neural stem cells (NSC). After four weeks of growth in the presence of 5 mM lithium, we observed a 35% reduction in DNA methylation at the Igf2/H19 DMD ( Figure 4B ). These results demonstrate that the effect of lithium on DNA methylation extends to neural cells, and expands the implications of our findings to other cell types.
Inactivation of Gsk-3 by PI3K results in Loss of
DNA Methylation at Imprinted Loci -Activated insulin signaling negatively regulates Gsk-3 activity via inhibitory phosphorylation of an Nterminal serine by Akt (41) . We investigated whether inactivation of Gsk-3 by constitutively active insulin signaling pathway could affect DNA methylation of imprinted genes. Expression of a myristoylated p110 subunit of PI3K (p110*) has previously been demonstrated to constitutively activate insulin signaling in ESCs (5). WT ESCs were stably transfected with p110*, and western blots were performed to verify activation of the insulin pathway. Stable expression of p110* leads to robust phosphorylation of Akt on serine 473, which results in the activation of Akt. In addition, we found increased N-terminal phosphorylation of both Gsk-3α (serine 21) and Gsk-3β (serine 9), suggesting that the cellular pool of Gsk-3 regulated by Akt is inhibited ( Figure 5A ). Bisulfite sequencing of the H19/Igf2 DMD and Igf2r DMR2 demonstrated a substantial reduction of DNA methylation levels in p110* stable cells, similar to that seen in Gsk-3 DKO ESCs ( Figures  5B, 5C ). These data demonstrate that activation of insulin signaling by constitutively active PI3K reduces DNA methylation at imprinted loci.
N-myc is a Potent Gsk-3-Dependent Regulator of Dnmt3a2
Gene Expression -Our data show that the reduced levels of DNA methylation at imprinted loci in Gsk-3 DKO ESCs are likely due to a decrease in Dnmt3a2 levels. To establish the mechanism by which Gsk-3 activity regulates the expression of Dnmt3a2, we considered that both Dnmt3a2 mRNA and protein levels are decreased in Gsk-3 DKO ESCs, suggesting that the effect is likely due to altered transcriptional regulation. A role for miRNAs was excluded since both Dnmt3a and Dnmt3a2 share a common 3' untranslated region (UTR), yet are not equally affected by loss of Gsk-3 isoforms. Therefore, we focused on understanding the mechanism controlling Dnmt3a2 transcription. A 1.9 kb fragment of the Dnmt3a2 promoter was cloned ( Figure 6A ), which is distinct from the regulatory regions of Dnmt3a, and had previously been shown to be sufficient for driving high levels of reporter expression in ESCs (24) . This 1.9 kb promoter fragment is capable of yielding robust (> 35 fold) expression of a luciferase reporter in WT ESCs ( Figure 6B ). The reporter also recapitulates the effect of Gsk-3 deletion on Dnmt3a2 mRNA, showing an approximately 40% reduction in reporter activity when transfected into Gsk-3 DKO ESCs.
In silico analysis of the Dnmt3a2 promoter revealed a region of highly conserved sequence just proximal to the exon unique to Dnmt3a2 which encodes the 5' UTR. Within this conserved region is a putative Myc binding site. Our microarray data showed a 2.8 fold decrease in Nmyc levels in Gsk-3 DKO ESCs. Real-time qPCR revealed an 8.8 fold decrease in N-myc mRNA ( Figure 6C) , and western blot analysis confirmed the corresponding decrease in N-myc protein by guest on August 17, 2017 http://www.jbc.org/ Downloaded from levels ( Figure 6D ). To test the importance of the Myc binding site in the Dnmt3a2 promoter, we performed site-directed mutagenesis on the putative Myc binding site in the context of the 1.9 kb promoter fragment, and transfected this reporter into ESCs. We observed a complete loss of reporter activity, confirming the functional importance of this binding site ( Figure 6B) . Finally, transfection of WT ESCs with N-myc siRNA resulted in a 77% reduction in N-myc levels ( Figure 6E ) and a decrease in Dnmt3a2 protein ( Figure 6F ), confirming the importance of N-myc on the regulation of Dnmt3a2 in ESCs.
DISCUSSION
Mechanisms to explain how extracellular environmental signals are transduced to the nucleus to affect epigenetic modifications, such as DNA methylation, have been elusive (44) . Here, we provide evidence for a novel role for Gsk-3 in the epigenetic regulation of imprinted genes. In mouse ESCs, deletion of Gsk-3 isoforms or expression of myristoylated PI3 kinase both lead to constitutive activation of downstream components of the insulin pathway, ultimately resulting in attenuated DNA methylation of imprinted loci. While we provide evidence that several imprinted genes are hypomethylated as a consequence of the loss of Gsk-3 activity, it remains to be determined whether DNA methylation is reduced at all known imprinted loci in Gsk-3 DKO ESCs, or if the effect on DNA methylation extends to non-imprinted genes.
Interestingly, we observed that ~90% of CpG dinucleotides analyzed in the Igf2/H19 DMD were methylated in WT ESCs. It is expected that the number of methylated CpG dinucleotides would be closer to 50% for this imprinted locus, since we did not discriminate between alleles in our bisulfite sequencing assay. The high amount of DNA methylation observed in WT ESCs is not likely due to PCR bias in our bisulfite sequencing procedure, as we observed 44% methylation of the Igf2/H19 DMD in neural stem cells (NSC) derived from WT mice using the same bisulfite sequencing assay (Supplemental Figure 1) . It has been reported that cultured ESC lines may exhibit almost complete methylation of the Igf2/H19 DMD on both parental alleles (33) . In light of these previously reported observations, it is likely that the high degree of DNA methylation we detect at the Igf2/H19 DMD in WT ESCs is due to biallelic methylation.
Our data shows an increase in N-terminal phosphorylation of Ser 9/Ser 21 on Gsk-3 isoforms upon ectopic expression of PI3K, resulting in decreased DNA methylation at the Igf2/H19 ICR. While our experimental approach utilized constitutively active PI3 kinase as a means of inducing phosphorylation on Gsk-3α S21/Gsk-3β S9, signal transduction of several pathways, such as protein kinase A (PKA) (45) , also result in Gsk-3α S21/Gsk-3β S9 phosphorylation. Therefore, our data predict that signaling pathways which lead to the phosphorylation and inhibition of Gsk-3 akin to insulin signaling would lead to decreased DNA methylation at imprinted loci. We have not ruled out the possibility that inactivation of Gsk-3 by Wnt signaling can lead to hypomethylation of Igf2/H19. Further investigation is needed to determine if activation of the Wnt pathway has the same effect on Dnmt3a2 expression.
The deficits we observe in DNA methylation are due to reduced levels of the de novo DNA methyltransferase Dnmt3a2. Dnmt3a2 co-purifies with Dnmt3L in ES cells, while Dnmt3a does not (46, 47) . Though Dnmt3L is catalytically inactive, it is required for establishment of DNA methylation at imprinted loci (48, 49) , and recruits Dnmt3a2 to DNA sequences associated with unmethylated lysine 4 of histone H3 (47). Dnmt3L levels were not significantly changed in Gsk-3 DKO ESCs (decreased 1.3 fold). These findings suggest that Dnmt3a2 plays a prominent role in the maintenance of DNA methylation at imprinted genes in early development. Heretofore, understanding the specific function of Dnmt3a2 in vivo has been difficult since targeted disruptions of the Dnmt3a locus in the mouse result in the simultaneous deletion of both Dnmt3a and Dnmt3a2, as the isoforms share common 3' exons. Our identification of a signal transduction pathway capable of specifically reducing levels of Dnmt3a2 provides a new approach for the study of this isoform in vivo.
To better understand the mechanism by which Dnmt3a2 mRNA is regulated, we cloned and analyzed a 1.9 kb fragment of mouse genomic DNA which contained a previously characterized promoter region. Computational analysis of the promoter revealed very little conservation of sequence across different species, with the exception of an approximately 200 bp region just upstream of the novel Dnmt3a2 exon. Within this region, we found a putative Myc binding site which is highly conserved, and a point mutation in this site completely impaired reporter activation. Recent chromatin immunoprecipitationsequencing (ChIP-Seq) data showed that both cmyc and N-myc share an identical DNA binding motif (50) ; however, we did not observe a reduction in c-myc protein in Gsk-3 DKO ESCs. Furthermore, ChIP-Seq data in mouse ESCs shows that N-myc, but not c-myc, binds specifically to the Dnmt3a2 promoter (50) . We have experimentally verified the importance of N-myc on regulating Dnmt3a2 expression by knocking down N-myc via siRNA. Taken together with the decreased levels of N-myc and unchanged levels of c-myc ( Figures S2A, S2B) , we conclude that Nmyc regulates Dnmt3a2 transcription. Gsk-3-mediated phosphorylation and degradation of cmyc and N-myc proteins by Gsk-3, has been reported in COS-7 cells (c-myc) and cerebellar granule neuron precursors (N-myc) (42, 43, 51) . We did not observe this regulation of myc proteins in our ESCs. In fact, we see an opposite effect of Gsk-3 on N-myc expression, and no effect on cmyc expression. Our data likely reflects cell-type specific differences in the regulation of myc proteins by Gsk-3. Furthermore, our real-time qPCR data indicates that N-myc downregulation in Gsk-3 DKO ESCs is occurring at the level of transcriptional regulation. The mechanism by which Gsk-3 regulates N-myc transcription in ESCs remains to be determined.
The ability of the Gsk-3 inhibitor lithium to phenocopy the reduction in DNA methylation of imprinted genes seen in Gsk-3 DKO ESCs is particularly intriguing. We have shown that DNA methylation is reduced at the Igf2/H19 ICR in both ESCs and NSCs after prolonged exposure to lithium. The effectiveness of lithium in the treatment of bipolar disorder was initially reported more than 60 years ago (52) . Lithium has been widely prescribed ever since, although the therapeutic mechanism of action has not been fully defined. Growing evidence suggests that alterations in DNA methylation have a role in the development of bipolar disorder (53, 54) . Our data raises the possibility that reduced DNA methylation of imprinted genes may be related to the mechanism of lithium action in bipolar disorder. It is noteworthy that another drug widely used for the treatment of bipolar disorder, valproic acid, also alters the epigenome by inhibiting histone deacetylase activity (55, 56) . In the context of our findings, it is tempting to speculate that lithium and valproic acid are effective in treating bipolar disorder because they modify the expression of a common subset of genes via changes in DNA methylation and histone acetylation, respectively.
Our findings may also provide a new focus for the study of neurological diseases. Gsk-3 activity has been linked to schizophrenia (57) , while alterations in the epigenome have been proposed to be a major factor in the development of schizophrenia (53) . Of the postnatal tissues which have been examined to date, imprinting is clearly predominant in the brain, and alterations in these imprinting events have been shown to affect behavior (58) . One example in humans is PraderWilli syndrome, which is caused by a deletion on chromosome 15q11-13, an area which contains the imprinted genes SNRPN and Necdin (NDN) (59) . This raises the possibility that altered Gsk-3 activity, resulting in aberrant DNA methylation of imprinted genes, could contribute to the development of schizophrenia or other behavioral disorders.
In summary, we have discovered a novel role for Gsk-3 in maintaining DNA methylation of imprinted loci in mouse ESCs. Since Gsk-3 is a nexus for numerous signal transduction pathways, the potential for Gsk-3 to regulate epigenetic changes could have profound consequences for our understanding of diverse human diseases.
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